Key points from article :
Casma Therapeutics has partnered with Vipergen, a leader in DNA-encoded library (DEL) technology, to advance drug discovery efforts targeting the autophagy pathway. Vipergen will leverage its cutting-edge DEL platform to identify novel small-molecule drug leads for a range of Casma’s undisclosed targets. Casma will retain exclusive rights to commercialize any resulting products globally, though financial terms of the deal remain confidential.
This collaboration brings together Casma’s expertise in harnessing autophagy—a natural cellular process that clears waste and repairs damage—with Vipergen’s innovative DEL technology. Together, they aim to tackle challenging protein targets and develop therapies addressing unmet medical needs. Jeff Saunders, Ph.D., Senior Vice President of Drug Discovery at Casma, highlighted the potential for Vipergen’s advanced chemistry to drive breakthroughs in patient care.
Vipergen CEO Nils Hansen, Ph.D., emphasized the opportunity to introduce high-quality hits and leads into Casma’s medicinal chemistry programs. The collaboration promises to unlock new pathways for small-molecule drug discovery, furthering Casma's mission to create transformative treatments for diseases linked to dysfunctional cellular processes.
